Advertisement
Advertisement

LYEL

LYEL logo

Lyell Immunopharma, Inc. Common Stock

22.97
USD
Sponsored
+0.33
+1.45%
Feb 06, 15:59 UTC -5
Closed
exchange

After-Market

22.71

-0.26
-1.13%

LYEL Earnings Reports

Positive Surprise Ratio

LYEL beat 14 of 18 last estimates.

78%

Next Report

Date of Next Report
Mar 09, 2026
Estimate for Q4 25 (Revenue/ EPS)
--
/
-$2.41
Implied change from Q3 25 (Revenue/ EPS)
-100.00%
/
+13.15%
Implied change from Q4 24 (Revenue/ EPS)
-100.00%
/
-39.75%

Lyell Immunopharma, Inc. Common Stock earnings per share and revenue

On Nov 12, 2025, LYEL reported earnings of -2.13 USD per share (EPS) for Q3 25, beating the estimate of -2.69 USD, resulting in a 20.98% surprise. Revenue reached 15.00 thousand, compared to an expected --, with a 0.00% difference. The market reacted with a -1.25% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 6 analysts forecast an EPS of -2.41 USD, with revenue projected to reach -- USD, implying an increase of 13.15% EPS, and decrease of -100.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Takeda Pharmaceutical Company Limited - ADR
Report Date
Jan 30, 2026 For Q3 26
Estimate
$34.44
Actual
$65.64
Surprise
+90.61%
FAQ
For Q3 2025, Lyell Immunopharma, Inc. Common Stock reported EPS of -$2.13, beating estimates by 20.98%, and revenue of $15.00K, 0% as expectations.
The stock price moved down -1.25%, changed from $17.63 before the earnings release to $17.41 the day after.
The next earning report is scheduled for Mar 09, 2026.
Based on 6 analysts, Lyell Immunopharma, Inc. Common Stock is expected to report EPS of -$2.41 and revenue of -- for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement